Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Merck
Novartis
Queensland Health
Mallinckrodt
Baxter
Dow
Healthtrust
McKesson
Colorcon

Generated: January 22, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 011792

« Back to Dashboard

NDA 011792 describes SOMA, which is a drug marketed by Mylan Speciality Lp, Meda Pharms, Ipsen Pharma, and Pharmacia And Upjohn, and is included in five NDAs. It is available from four suppliers. There are two patents protecting this drug. Additional details are available on the SOMA profile page.

The generic ingredient in SOMA is pegvisomant. One supplier is listed for this compound. Additional details are available on the pegvisomant profile page.
Summary for 011792
Tradename:SOMA
Applicant:Mylan Speciality Lp
Ingredient:carisoprodol
Patents:0
Therapeutic Class:Skeletal Muscle Relaxants
Formulation / Manufacturing:see details
Pharmacology for NDA: 011792
Medical Subject Heading (MeSH) Categories for 011792
Suppliers and Packaging for NDA: 011792
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
SOMA carisoprodol CAPSULE;ORAL 011792 NDA Meda Pharmaceuticals 0037-2001 0037-2001-01 100 TABLET in 1 BOTTLE, PLASTIC (0037-2001-01)
SOMA carisoprodol CAPSULE;ORAL 011792 NDA Meda Pharmaceuticals 0037-2250 0037-2250-30 30 TABLET in 1 BOTTLE, PLASTIC (0037-2250-30)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength350MG
Approval Date:Approved Prior to Jan 1, 1982TE:AARLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:DISCNDosage:CAPSULE;ORALStrength250MG
Approval Date:Approved Prior to Jan 1, 1982TE:RLD:No

Profile for product number 004

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength250MG
Approval Date:Sep 13, 2007TE:ABRLD:Yes

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Deloitte
Dow
McKinsey
Merck
McKesson
US Department of Justice
Cipla
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot